Chinese Journal of Practical gynecology ang obstetric ›› 2023, Vol. 39 ›› Issue (7): 698-701.DOI: 10.19538/j.fk2023070106

Previous Articles     Next Articles

Neoadjuvant chemotherapy in vulvar cancer. 

  

  1. Department of Obstetrics and Gynecology,Peking University People’s Hospital,Beijing 100044,China 
  • Online:2023-07-02 Published:2023-07-02

外阴癌新辅助化疗

  

  1. 北京大学人民医院妇产科,北京 100044
  • 通讯作者: 王建六
  • 基金资助:
    国家重点研发计划(2022YFC2704400)

Abstract: The incidence rate of vulvar cancer is low and the management is complex,especially in patients with locally advanced vulvar cancer. In recent years,researches on neoadjuvant chemotherapy for vulvar cancer have gradually increased. Through neoadjuvant chemotherapy,tumor lesions can be reduced to avoid surgical removal of organs such as the urethra and anus,preserving organ function,and improving patient quality of life. However,there are still relatively few studies at present,and most of them are retrospective studies. Further research is still needed to evaluate the therapeutic effect and neoadjuvant chemotherapy regimen.

Key words: vulvar cancer, neoadjuvant chemotherapy, prognosis

摘要: 外阴癌的发病率低,处理相对复杂,尤其是局部晚期外阴癌患者。近些年以来,有关外阴癌新辅助化疗的研究逐渐增多,通过新辅助化疗可缩小肿瘤病灶,避免手术切除尿道、肛门等器官,保留脏器功能,提高患者生活质量。但目前研究仍然较少,且多数为回顾性研究,仍需要进一步深入研究评估其治疗效果及新辅助化疗方案。

关键词: 外阴癌, 新辅助化疗, 预后

CLC Number: